Caribou Biosciences, Inc. (NASDAQ: CRBU)

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies using its novel chRDNA genome-editing technology. The company focuses on allogeneic, or off-the-shelf, chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies. Its core activities involve engineering donor-derived T cells with precise genomic edits to enhance efficacy, safety, and manufacturability of cell therapies.

Caribou Biosciences generates revenue through the advancement and potential commercialization of its clinical-stage product candidates, primarily vispa-cel and CB-011. The company does not currently have approved products generating revenue but is developing these therapies for eventual sale to healthcare providers and patients. Revenue generation is expected upon regulatory approval and market launch of its allogeneic CAR-T cell therapies targeting CD19 and BCMA antigens.

The company operates through the following segments: Allogeneic CAR-T Cell Therapies and Genome-Editing Technology Development.

• Allogeneic CAR-T Cell Therapies: This segment encompasses the research, development, and clinical evaluation of off-the-shelf CAR-T cell therapies for hematologic malignancies. The segment includes vispa-cel (formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy being evaluated for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. Both product candidates incorporate the company’s chRDNA technology to armoring strategies such as TCR knockout, PD-1 disruption, and immune cloaking via B2M removal and HLA-E insertion to enhance persistence and antitumor activity.

• Genome-Editing Technology Development: This segment involves the innovation and application of the proprietary chRDNA (CRISPR hybrid RNA-DNA) platform, which combines RNA and DNA nucleotides in guide molecules to improve editing specificity and efficiency. The technology enables multiplex gene editing, including knockouts and site-specific insertions, using Cas9 or Cas12a proteins without reliance on lentiviral or retroviral vectors. The segment supports the development of allogeneic CAR-T therapies and has broader potential for ex vivo and in vivo cell and gene therapies across oncology, autoimmune diseases, and other therapeutic areas.

Caribou Biosciences occupies a specialized position in the competitive landscape of cell therapy and genome editing, differentiating itself through its chRDNA technology, which offers improved specificity and reduced off-target effects compared to first-generation CRISPR systems. The company competes with established autologous CAR-T providers such as Novartis (Kymriah), Kite Pharma (Yescarta, Tecartus), and Bristol-Myers Squibb (Breyanzi, Abecma), as well as allogeneic competitors like Allogene Therapeutics, Fate Therapeutics, and CRISPR Therapeutics. Its competitive advantages include off-the-shelf availability, potential for lower manufacturing costs, and enhanced product durability through genome-editing armoring strategies.

The company serves patients with relapsed or refractory hematologic malignancies, including those with B-cell non-Hodgkin lymphoma and multiple myeloma, who are ineligible for or have exhausted conventional therapies. Its customer base comprises healthcare providers, treatment centers, and patients seeking advanced cell therapy options, particularly in community and academic hospital settings where access to autologous CAR-T is limited.